MEDICENNA THERAPEUTICS CORP (MDNA.CA) Stock Price, Forecast & Analysis
Canada - Toronto Stock Exchange - TSX:MDNA - CA58490H1073 - Common Stock
MDNA.CA Key Statistics, Chart & Performance
The current stock price of MDNA.CA is 0.95 CAD. In the past month the price decreased by -39.87%. In the past year, price decreased by -30.66%.
MDNA.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| EPRX.CA | EUPRAXIA PHARMACEUTICALS INC | N/A | 517.64M | ||
| EDT.CA | SPECTRAL MEDICAL INC | N/A | 401.93M | ||
| HBP.CA | HELIX BIOPHARMA CORP | N/A | 170.33M | ||
| COV.CA | COVALON TECHNOLOGIES LTD | 26.14 | 50.54M | ||
| MBX.CA | MICROBIX BIOSYSTEMS INC | N/A | 33.36M | ||
| RVX.CA | RESVERLOGIX CORP | N/A | 28.73M | ||
| BCT.CA | BRIACELL THERAPEUTICS CORP | N/A | 18.59M | ||
| HEM.CA | HEMOSTEMIX INC | N/A | 16.96M | ||
| MPH.CA | MEDICURE INC | N/A | 11.90M | ||
| CSCI.CA | COSCIENS BIOPHARMA INC | N/A | 9.19M | ||
| QPT.CA | QUEST PHARMATECH INC | N/A | 6.77M | ||
| KNE.CA | KANE BIOTECH INC | N/A | 6.69M |
Related stock screener links
About MDNA.CA
Company Profile
Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company. The company is headquartered in Toronto, Ontario and currently employs 18 full-time employees. The company went IPO on 2015-07-13. Its long-acting IL-2 Superkine, MDNA11, is a IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Its IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials, including a Phase IIb trial for recurrent glioblastoma (GBM). Its early-stage high-affinity IL-2B biased IL-2/IL-15 Super-antagonists, from its MDNA209 platform, are being evaluated as potential therapies for autoimmune and graft-versus host diseases. Its early-stage BiSKITs (Bifunctional SuperKine ImmunoTherapies) and the T-MASK (Targeted Metalloprotease Activated SuperKine) programs are designed to enhance the ability of Superkines to treat immunologically cold tumors.
Company Info
MEDICENNA THERAPEUTICS CORP
2 Bloor St W., 7Th Floor
TORONTO ONTARIO M4S 3E2 CA
CEO: Gino L. DeMichele
Employees: 16
Phone: 14166485555
MEDICENNA THERAPEUTICS CORP / MDNA.CA FAQ
Can you describe the business of MEDICENNA THERAPEUTICS CORP?
Medicenna Therapeutics Corp. is a clinical stage immuno-oncology company. The company is headquartered in Toronto, Ontario and currently employs 18 full-time employees. The company went IPO on 2015-07-13. Its long-acting IL-2 Superkine, MDNA11, is a IL-2 with superior affinity toward CD122 (IL-2 receptor beta) and no CD25 (IL-2 receptor alpha) binding, thereby preferentially stimulating cancer-killing effector T cells and NK cells. Its IL-4 Empowered Superkine, bizaxofusp, has been studied in five clinical trials, including a Phase IIb trial for recurrent glioblastoma (GBM). Its early-stage high-affinity IL-2B biased IL-2/IL-15 Super-antagonists, from its MDNA209 platform, are being evaluated as potential therapies for autoimmune and graft-versus host diseases. Its early-stage BiSKITs (Bifunctional SuperKine ImmunoTherapies) and the T-MASK (Targeted Metalloprotease Activated SuperKine) programs are designed to enhance the ability of Superkines to treat immunologically cold tumors.
Can you provide the latest stock price for MEDICENNA THERAPEUTICS CORP?
The current stock price of MDNA.CA is 0.95 CAD. The price increased by 2.15% in the last trading session.
Does MDNA stock pay dividends?
MDNA.CA does not pay a dividend.
What is the ChartMill rating of MEDICENNA THERAPEUTICS CORP stock?
MDNA.CA has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
Can you provide the PE ratio for MDNA stock?
MEDICENNA THERAPEUTICS CORP (MDNA.CA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.17).
What is MEDICENNA THERAPEUTICS CORP worth?
MEDICENNA THERAPEUTICS CORP (MDNA.CA) has a market capitalization of 79.24M CAD. This makes MDNA.CA a Micro Cap stock.
MDNA.CA Technical Analysis
MDNA.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to MDNA.CA. MDNA.CA scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
MDNA.CA Financial Highlights
Over the last trailing twelve months MDNA.CA reported a non-GAAP Earnings per Share(EPS) of -0.17. The EPS increased by 54.05% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -76.58% | ||
| ROE | -134.89% | ||
| Debt/Equity | 0.01 |
MDNA.CA Forecast & Estimates
10 analysts have analysed MDNA.CA and the average price target is 4.26 CAD. This implies a price increase of 348.63% is expected in the next year compared to the current price of 0.95.